Diagnostic utility of plasma p-tau217 differs by Alzheimer's disease tau-based subtypes.
Hojjati SH, Butler TA, Zare SJM, Reihanian A, Khalafi M, Foldi N, Shah S, Jafari H, Li Y, Zhou L, Dartora W, Wartchow K, McIntire LBJ, Chiang GC; Alzheimer's Disease Neuroimaging Initiative.
Hojjati SH, et al.
Alzheimers Dement (Amst). 2025 Nov 26;17(4):e70227. doi: 10.1002/dad2.70227. eCollection 2025 Oct-Dec.
Alzheimers Dement (Amst). 2025.
PMID: 41322377
Free PMC article.
INTRODUCTION: Blood-based biomarkers, most notably plasma phosphorylated tau (p-tau)217, have transformed the diagnostic landscape of Alzheimer's disease (AD). METHODS: We applied an unsupervised machine learning approach to tau positron emission tomography (PET) imaging i …
INTRODUCTION: Blood-based biomarkers, most notably plasma phosphorylated tau (p-tau)217, have transformed the diagnostic landscape of Alzhei …